Roflumilast Foam 0.3% + Vehicle foam
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Seborrheic Dermatitis
Conditions
Seborrheic Dermatitis
Trial Timeline
Dec 4, 2019 → Aug 21, 2020
NCT ID
NCT04091646About Roflumilast Foam 0.3% + Vehicle foam
Roflumilast Foam 0.3% + Vehicle foam is a phase 2 stage product being developed by Arcutis Biotherapeutics for Seborrheic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04091646. Target conditions include Seborrheic Dermatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05028582 | Phase 3 | Completed |
| NCT04128007 | Phase 2 | Completed |
| NCT04091646 | Phase 2 | Completed |
Competing Products
15 competing products in Seborrheic Dermatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elidel + Ketoconazole Cream | Novartis | Phase 2 | 52 |
| PF-07038124 + Placebo Ointment | Pfizer | Phase 2 | 51 |
| Ketoconazole | GSK plc | Approved | 84 |
| Azelaic Acid 15% Gel + Inactive 15% gel base | Bayer | Phase 2 | 49 |
| Ruxolitinib 1.5% Cream | Incyte | Phase 2 | 49 |
| Roflumilast Foam + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 72 |
| ARQ-154 | Arcutis Biotherapeutics | Phase 2 | 47 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 Topical Solution | Aclaris Therapeutics | Approved | 77 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle | Aclaris Therapeutics | Phase 1/2 | 33 |
| A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution | Aclaris Therapeutics | Phase 2 | 44 |